中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

PROFIT ALERT – EXPECTED REDUCTION IN LOSS

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**" or "**Ab&B Bio-Tech**", together with its subsidiary, the "**Group**") pursuant to the Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders and potential investors of the Company that based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 ("**FY2025**"), the Group is expected to record a revenue in the range of approximately RMB446 million to RMB493 million for FY2025, representing an increase of approximately 71.8% to 89.9% as compared to a revenue of RMB259.6 million for the year ended December 31, 2024, and is expected to record a net loss in the range of approximately RMB157 million to RMB197 million for FY2025, representing a reduction of approximately 23.9% to 39.3% as compared to a net loss of RMB258.7 million for the year ended December 31, 2024.

The Board believes that the aforementioned increase in revenue and reduction in net loss is primarily attributable to:

1. The Company has continued to strengthen its quality management capabilities, using information technology to support smart manufacturing and oversight. This has resulted in a 100% qualification rate for all product batches released, which contributed to a decrease in cost of sales;

2. The Company has adopted digital marketing tools to enhance its sales strategy and execution. These tools include real-time sales data analysis using large-scale data models, customer segmentation and scenario testing to refine strategies, and tailored marketing policies. In addition, the Company has conducted large-scale post-market product evaluation studies and academic research on special populations, including pregnant women and patients with nephrotic syndrome. The Company has also expanded its academic promotion efforts from provincial, municipal and district levels down to end-point coverage of local markets and consumers in approved regions. The more targeted and data-driven approach to marketing has improved the efficiency of promotional spending, contributing to a reduction in selling expenses while supporting revenue growth;

3. The Company's product distribution network expanded further in 2025 compared to 2024, adding 232 disease control centers and 2,563 vaccination clinics. As a result, the Company's products are now accessible to consumers across a greater number of regions than in the previous year, directly contributing to an increase in revenue;

4. While continuing to invest in research and development, the Company has made initial progress in reducing costs and improving operational efficiency. Although the Group's listing expenses increased significantly in 2025, the combined effect of revenue growth and tightened cost controls has resulted in a narrowing of net losses during FY2025.

The Board wishes to emphasize that the information contained in this announcement is only a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Group for FY2025. The information contained in this announcement has not been audited or reviewed by the Company's auditor and is subject to adjustments and changes. Details of the Group's financial results and performance for FY2025 will be disclosed in the Company's annual results announcement, which is expected to be published at the end of March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, February 26, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.